(Posted By: Josi Creek)
CAMBRIDGE,
Mass., Apr 05, 2010 (BUSINESS WIRE) ----Biogen Idec (NASDAQ: BIIB)
today announced that 38 company-sponsored platform and poster
presentations will be presented during the American Academy of
Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 -- 17,
2010. The AAN Annual Meeting is the world's largest gathering of
neurologists. These presentations include data on five compounds
that are marketed or currently in development by Biogen Idec and its
partners for the treatment of multiple sclerosis (MS), including
two approved therapies for MS, TYSABRI(R) (natalizumab) and
AVONEX(R) (interferon beta-1a), and three promising compounds in the
late stages of development: BG-12 (dimethyl fumarate), PEGylated
interferon beta-1a and daclizumab.
